(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/215978 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2024/024201

(22) International Filing Date:
12 April 2024 (12.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/496,205 14 April 2023 (14.04.2023) US

(71) Applicant: **INCYTE CORPORATION** [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: **WANG, Liang-Chuan**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **SUN, Chifei**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **ASATIANI, Ekaterine**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(74) Agent: **GUZZO, Catherine** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: USE OF AN ANTI-TGFBETAR2/PD-1 BISPECIFIC ANTIBODY TO TREAT CANCER




FIG. 2A

(57) Abstract: The present disclosure describes a bispecific antibody targeting human programmed death-1 (PD-1) and human transforming growth factor β receptor 2 (TGFβR2) for use in the treatment of disorder such as non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), ovarian cancer, breast cancer, bladder cancer, renal cell carcinoma, melanoma, gastric adenocarcinoma, esophageal cancer, gastroesophageal adenocarcinoma, malignant pleural mesothelioma, pancreatic adenocarcinoma, and colorectal cancer (CRC).

WO 2024/215978 A1